# US 6,355,625 B1 · Compositions of β-glucans and specific IGIV

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,355,625 B1
- Document ID: US6355625B1
- Status: Granted
- Kind: B1
- Application number: 09/395,360
- Filed: 1999-09-14
- Granted: 2002-03-12
- Earliest claimed: 1998-09-14
- Assignees: Nabi
- Inventors: Viliam Pavliak; Ali Ibrahim Fattom; Robert B. Naso
- Web page: https://patentgrep.com/patent/US6355625B1

## CPC

- A61K 39/40: bacterial
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions and kits comprising combinations of β-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which β-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.

## Claims

### Claim 1

A composition comprising a β-glucan and hyperimmune specific IGIV.

### Claim 2 (depends on 1)

A composition according to claim 1, wherein said β-glucan is a soluble β-glucan.

### Claim 3 (depends on 2)

A composition according to claim 2, wherein said soluble β-glucan is a chemically-derivatized β-glucan.

### Claim 4 (depends on 3)

A composition according to claim 3, wherein said chemically-derivatized β-glucan is selected from the group consisting of carboxymethyl glucan, sulfoethyl glucan, glucuronoglucan, glucan sulfate, phosphorylated glucan, and glucan amine.

### Claim 5 (depends on 1)

A composition according to claim 1, wherein said β-glucan is a (1→3)β-glucan.

### Claim 6 (depends on 1)

A composition according to claim 1, wherein said hyperimmune specific IGIV is specific to S. aureus.

### Claim 7 (depends on 6)

A composition according to claim 6, comprising hyperimmune specific IGIV specific to a S. aureus antigen that comprises β-linked hexosamine, that contains no O-acetyl groups detectable by nuclear magnetic resonance spectroscopy and that reacts with antibodies to ATCC 55804.

### Claim 8 (depends on 6)

A composition according to claim 6, comprising hyperimmune specific IGIV specific to a S. epidermidis antigen.

### Claim 9 (depends on 6)

A method according to claim 6, comprising hyperimmune specific IGIV specific to a S. aureus antigen that comprises β-linked hexosamine, that contains no O-acetyl groups detectable by nuclear magnetic resonance spectroscopy and that reacts with antibodies to ATCC 55804.

### Claim 10 (depends on 6)

A method according to claim 6, comprising hyperimmnune specific IGIV specific to a S. epidermidis antigen.

### Claim 11 (depends on 1)

A composition according to claim 1, wherein said hyperimmune specific IGIV is specific to Type 5 antigen or Type 8 antigen.

### Claim 12 (depends on 1)

A composition according to claim 1, wherein said hyperimmnune specific IGIV is specific to an Enterococcus antigen.

### Claim 13 (depends on 12)

A composition according to claim 12, wherein said hyperimmune specific IGIV is specific to an E. faecalis or E. faecium antigen.

### Claim 14 (depends on 12)

A method according to claim 12, wherein said hyperimmune specific IGIV is specific to an E. faecalis or E. faecium antigen.

### Claim 15 (depends on 1)

A method according to claim 1, wherein said hyperimmune specific IGIV is specific to S. aureus.

### Claim 16 (depends on 1)

A method according to claim 1, wherein said hyperimmune specific IGIV is specific to Type 5 antigen or Type 8 antigen.

### Claim 17 (depends on 1)

A method according to claim 1, wherein said hyperimmune specific IGIV is specific to an Enterococcus antigen.

### Claim 18 (depends on 1)

A composition according to claim 1, wherein said hyperimmune specific IGIV contains antibodies specific to a pathogenic microorganism.

### Claim 19

A kit comprising:
a β-glucan;
hyperimmune specific IGIV; and
instructions for sequential administration of said β-glucan and said hyperimmune specific IGIV.

### Claim 20 (depends on 19)

A kit according to claim 19, wherein said hyperimmune specific IGIV contains antibodies specific to a pathogenic microorganism.

### Claim 21

A method of preventing of treating infection by a pathogenic microorganism, comprising:
administering β-glucan to a subject; and
introducing hyperimmnune specific IGIV into said subject.

### Claim 22 (depends on 21)

A method according to claim 21, wherein said β-glucan is a soluble β-glucan.

### Claim 23 (depends on 22)

A method according to claim 22, wherein said β-glucan is a chemically-derivatized β-glucan is selected from the group consisting of carboxymethyl glucan, sulfoethyl glucan, glucuronoglucan, glucan sulfate, phosphorylated glucan, and glucan amine.

### Claim 24 (depends on 21)

A method according to claim 21 , wherein said hyperimmune specific IGIV contains antibodies specific to a pathogenic microorganism.